Edgar Filing: ANTARES PHARMA, INC. - Form 4

	HARMA, INC.										
Form 4)										
May 16, 2008									OMB A	PPROVAL	
FORM	UNITEDS	TATES SI			ND EXC D.C. 205		IGE (COMMISSION		3235-0287	
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed purs Section 17(a	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940								Expires: January 31, 2005 Estimated average burden hours per response 0.5	
(Print or Type R	esponses)										
APPLE ROBERT F Sy			2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [AIS]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) (M RES PHARMA, HILLIPS BLVD,	(M 05	Date of 1 10nth/Da 5/14/20	-	ansaction			Director X Officer (give below)	10%	Owner er (specify	
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
EWING, NJ	08618								Iore than One Re		
(City)	(State) (2	Zip)	Table	I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	Code	on(A) or Dis (D)	posed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	05/14/2008			А	27,500 (1)	A	<u>(2)</u>	72,954	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 2. 4. 7. Title and Amount of 8 Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities Ľ Security or Exercise any Code Securities (Month/Day/Year) (Instr. 3 and 4) S Price of (Month/Day/Year) (Instr. 8) (Instr. 3) Acquired (A) (Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Amount Expiration Date or Title Exercisable Date Number Code V (A) (D) of Shares Stock Option Common \$ 0.85 05/14/2008 82,500 (3) 05/13/2018 82,500 Α Stock (right to buy)

Edgar Filing: ANTARES PHARMA, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
APPLE ROBERT F C/O ANTARES PHARMA, INC. 250 PHILLIPS BLVD, SUITE 290 EWING, NJ 08618			Senior VP and CFO				
Signatures							

/s/ Robert F. Apple <u>**</u>Signature of Reporting Person 05/16/2008 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents grant of shares of restricted Common Stock issued under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments.
- (2) Not applicable.
- (3) The option vests in equal quarterly installments over three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.